Respiratory Test Kit Tyfast Flu A+B / COVID-19 Multiplex Rapid Test 25 Tests - ACT21001-25
by CorDx Inc
In Stock
$286.99
SKU ACT21001-25
Spring Savings: Use code FALL for 5% OFF Total Purchase
Free Shipping Orders Over $100
Questions? Speak with a specialist!
Chat with us!
Click Widget Below
Give us a call!
Email us!
Features:
- The CorDx Tyfast Flu A/B & COVID-19 Multiplex Rapid Test is only for in vitro diagnostic use under the Food and Drug Administration’s Emergency Use Authorization: https://www.fda.gov/medical-devices/covid-19-emergency-use-authorizations-medical-devices/in-vitro-diagnostics-euas-antigen-diagnostic-tests-sars-cov-2
- Product ships with minimum 90 days dating
- The CorDx Tyfast Flu A/B & COVID-19 Multiplex Rapid Test is a lateral flow immunochromatographic assay intended for in vitro rapid, simultaneous qualitative detection and differentiation of influenza A and influenza B nucleoprotein antigens and SARS-CoV-2 nucleocapsid antigen directly from anterior nasal swab specimens of individuals with signs and symptoms of respiratory infection consistent with COVID-19 by their healthcare provider within the first five (5) days of symptom onset when tested at least twice over three days with at least 48 hours between tests
- The test provides an efficient and accurate diagnostic solution in 10 mins, giving healthcare providers and communities a rapid and reliable way to prioritize their health
- Testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. § 263a, that meet the requirements to perform moderate, high or waived complexity tests
- This test is authorized for use at the Point of Care (POC), i.e., in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation
- Results are for the simultaneous in vitro detection and differentiation of SARS-CoV-2, influenza A virus, and influenza B virus protein antigens, but do not differentiate, between SARS-CoV and SARS-CoV-2 viruses and are not intended to detect influenza C antigens
- Positive results do not rule out bacterial infection or co-infection with other viruses
- Negative results do not rule out influenza or SARS-CoV-2 infection, and should not be used as the sole basis for treatment or patient management decisions, including infection control measures such as isolating from others and wearing masks
Product Specifications:
| Manufacture # | ACT21001-25 |
|---|---|
| Brand | Tyfast |
| Manufacturer | CorDx Inc |
| Country of Origin | United States |
| Application | Respiratory Test Kit |
| Contents 1 | (25) Test Cassettes, (25) Swabs, (25) Tubes with Sample Processing Solution, IFU, Quick Ref Guide |
| Number of Tests | 25 Tests |
| Product Dating | McKesson Acceptable Dating: we will ship >= 90 days |
| Purchase Program Type | Standard Purchase |
| Reading Type | Visual Read |
| Sample Type | Anterior Nasal Swab Sample |
| Specialty | Immunoassay |
| Test Format | Cassette Format |
| Test Kit Type | Rapid |
| Test Method | Lateral Flow |
| Test Name | Flu A+B / COVID-19 Multiplex Rapid Test |
| Time to Results | 10 Minute Results |